- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Large Cap High Growth Potential
Global Pharmaceuticals & Biotech Large Cap High Growth Potential
UPDATED Apr 22, 2024
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
43 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
ALNY | US$145.79 | -0.6% | -27.9% | US$18.4b | US$220.00 | PS10.1x | E60.6% | n/a | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | ||
603392 | CN¥66.04 | -5.8% | -12.4% | CN¥83.8b | CN¥75.15 | PE67.1x | E54.8% | 0.5% | ||
SRPT | US$116.96 | -0.3% | -5.1% | US$11.0b | US$164.54 | PS8.8x | E42.7% | n/a | ||
NBIX | US$133.66 | 0.5% | 30.6% | US$13.4b | US$152.48 | PE53.8x | E26.6% | n/a | ||
KRTX | US$329.83 | 3.3% | 80.7% | US$12.6b | US$326.92 | PS19238.9x | E60.1% | n/a | ||
LLY | US$731.33 | -2.1% | 90.0% | US$658.8b | US$813.32 | PE125.7x | E27.2% | 0.7% | ||
ARGX | €337.10 | -3.5% | -5.9% | €20.0b | €439.38 | PS16.8x | E56.1% | n/a | ||
500420 | ₹2,636.30 | 3.9% | 60.6% | ₹892.2b | ₹2,728.41 | PE59.7x | E21.3% | 1.1% | ||
MEDP | US$376.26 | -2.3% | 80.7% | US$11.7b | US$402.04 | PE41.2x | E14.7% | n/a | ||
AZN | UK£112.50 | 3.4% | -8.5% | UK£174.4b | UK£130.75 | PE36.2x | E16.3% | 2.0% | ||
SDZ | CHF31.02 | 11.1% | n/a | CHF13.3b | CHF35.13 | PE189.8x | E29.7% | 1.4% | ||
4568 | JP¥4,663.00 | 2.3% | -2.8% | JP¥8.9t | JP¥5,620.00 | PE48.1x | E21.9% | 1.3% | ||
EXAS | US$62.41 | -2.3% | -1.8% | US$11.3b | US$89.27 | PS4.5x | E61.9% | n/a | ||
MRK | US$126.94 | 1.5% | 8.9% | US$321.5b | US$137.58 | PE880.9x | E25.9% | 2.4% | ||
ABBV | US$167.89 | 3.3% | 1.8% | US$297.3b | US$184.14 | PE61.7x | E23.4% | 3.7% | ||
DIM | €196.50 | -22.2% | -18.6% | €19.1b | €252.92 | PE75.1x | E23.3% | 0.4% | ||
INCY | US$51.92 | -2.4% | -29.4% | US$11.7b | US$75.68 | PE19.5x | E20.1% | n/a | ||
DIVISLAB | ₹3,768.65 | 0.1% | 16.8% | ₹992.2b | ₹3,442.36 | PE72.3x | E23.9% | 0.8% | ||
UCB | €122.00 | 2.2% | 38.7% | €23.1b | €122.71 | PE67.5x | E25.2% | 1.1% | ||
GMAB | kr.2,008.00 | -2.4% | -28.9% | kr.131.7b | kr.2,434.00 | PE29.9x | E21.7% | n/a | ||
MANKIND | ₹2,393.05 | 4.9% | n/a | ₹958.6b | ₹2,184.17 | PE55.5x | E18.7% | n/a | ||
BGNE | US$130.94 | -2.3% | -46.9% | US$13.7b | US$268.64 | PS5.6x | E56.2% | n/a | ||
TEVA | US$12.88 | -1.6% | 56.5% | US$14.6b | US$15.74 | PB1.9x | E32.1% | 0% |